Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus investigator's choice in advanced melanoma after anti-CTLA-4
2012-001828-35Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective response rate (ORR) in nivolumab treatment group and Overall survival (OS) comparison. Started Nov 2012; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-001828-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001828-35.